Phase II FORTE: Efficacy of KRd With or Without ASCT in Newly Diagnosed Multiple Myeloma According to Risk Status

May 31 - June 4, 2019; Chicago, Illinois
Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: June 3, 2019

Acknowledgements

Provided by the USF Health

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Amgen
Celgene Corporation

Related Content

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

From Clinical Care Options (CCO), an on-demand Webcast with Dr. Shaji Kumar on advances in care for people with multiple myeloma

Sarah A. Holstein, MD, PhD
Program Director
Jonathan L. Kaufman, MD
Program Director
Shaji Kumar, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 20, 2020 Expired: November 19, 2021

Expert overview of treatment strategies with antibody-drug conjugates and bispecific antibodies and T-cell engagers targeting BCMA in patients with myeloma from CCO

Natalie S. Callander, MD Released: November 12, 2020

A Clinical Care Options downloadable PDF guide to clinical trials of BCMA agents for multiple myeloma that are currently recruiting patients

Released: November 5, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue